---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-138446"
form_type: "8-K"
ticker: "ENGN"
cik: "0001980845"
company_name: "enGene Therapeutics Inc."
filed_at: "2024-12-19T23:59:59+00:00"
generated_at: "2026-05-29T01:48:39.819170+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# enGene reports FY2024 net loss $55.1M; cash $297.9M; LEGEND study on track for mid-2026 BLA

## Summary
- Net loss $55.1M ($1.46/sh) vs $104.7M in FY2023; operating expenses $62.3M up from $26.1M.
- Cash, cash equivalents and marketable securities $297.9M; expected to fund operations into 2027.
- Preliminary LEGEND pivotal data: 71% anytime CR rate in BCG-unresponsive NMIBC with CIS; BLA filing on track for mid-2026.
- First Amendment with Hercules Capital reallocates $7.5M to Tranche 3; total $50M facility unchanged.
- Appointed Joan Connolly as CTO, Anthony Cheung as CSO, Alex Nichols as Chief Strategy & Operations Officer.

## SEC filing metadata
- accession: 0000950170-24-138446
- form_type: 8-K
- ticker: ENGN
- cik: 0001980845
- company_name: enGene Therapeutics Inc.
- filed_at: 2024-12-19T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.02, 2.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1980845/000095017024138446/0000950170-24-138446-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1980845/000095017024138446/engn-20241219.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-138446
- JSON: https://secwatch.observer/filing/0000950170-24-138446.json
- Plain text: https://secwatch.observer/filing/0000950170-24-138446.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.